Pay in 4 interest-free payments of $5.87 Learn more
Ships within 48 hours · Estimated delivery Sep 8 - Sep 13
Not all of these options meet the necessary safety and quality standards
[1] The more advanced regulatory activity belongs to the combination product CagriSema (cagrilintide plus semaglutide), which reached Phase 3 and for which a New Drug Application was reported to have been filed with the FDA in late 2025
I am not surprised that Connecticut would back off of this, because I'm sure that if they had any conversations with those original manufacturers, they weren't very pleased about that plan and probably not especially excited about helping to support that, Tinker said
The mechanisms of these medications conflict fundamentally with eating disorder recovery principles
Because of this, the FDA put a black box warning on all these types of medications to not use it for patients with a history or family history of medullary thyroid cancer
